Mural Oncology (NASDAQ:MURA) Downgraded by Raymond James to Outperform

Raymond James downgraded shares of Mural Oncology (NASDAQ:MURA) from a strong-buy rating to an outperform rating in a report published on Tuesday, MarketBeat.com reports. They currently have $18.00 price target on the stock.

Several other research firms also recently weighed in on MURA. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a research note on Wednesday, March 12th. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.00.

Mural Oncology Trading Down 61.6 %

Shares of Mural Oncology stock opened at $1.47 on Tuesday. The business has a fifty day simple moving average of $3.87 and a two-hundred day simple moving average of $3.61. The firm has a market capitalization of $25.33 million, a P/E ratio of -0.16 and a beta of 3.66. Mural Oncology has a 12 month low of $1.37 and a 12 month high of $5.12.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter in the prior year, the firm earned ($3.57) EPS. Analysts predict that Mural Oncology will post -7.54 earnings per share for the current year.

Institutional Investors Weigh In On Mural Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Acorn Capital Advisors LLC bought a new position in Mural Oncology in the 4th quarter valued at approximately $4,141,000. Renaissance Technologies LLC raised its stake in shares of Mural Oncology by 17.4% in the fourth quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock worth $768,000 after purchasing an additional 35,403 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Mural Oncology by 2.6% during the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after purchasing an additional 4,731 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Mural Oncology by 1.4% during the fourth quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock valued at $565,000 after buying an additional 2,470 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Mural Oncology during the third quarter valued at $340,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.